US2005101635A1PendingUtilityA1

Compositions and methods for treating or preventing diseases of body passageways

62
Assignee: UNIV BRITISH COLUMBIAPriority: May 24, 1996Filed: Oct 21, 2004Published: May 12, 2005
Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay Machan
A61P 31/06A61P 9/10A61P 9/00A61P 35/00A61P 31/04A61P 43/00A61P 27/02A61K 9/1652A61P 11/00A61P 13/08A61K 9/5031A61K 47/34A61P 1/04A61K 9/0024A61K 9/167A61K 31/337A61K 9/1075A61K 9/5146A61K 9/70A61K 31/28A61K 9/5153A61K 9/12A61P 13/02A61K 31/00A61P 15/00A61K 9/5138A61K 9/1635A61P 11/08A61K 9/1647A61K 31/335A61K 9/5192A61P 1/00A61K 9/10A61K 9/7007A61P 13/00A61K 33/24
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to an external portion of the body passageway of a patient in need thereof a therapeutically effective amount of an antihistamine or decongestant or a composition comprising an antihistamine or decongestant, such that the inflammatory disease is treated.  
     
     
         2 . The method of  claim 1  wherein the inflammatory disease is a gastrointestinal tract disease.  
     
     
         3 . The method of  claim 2  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         4 . The method of  claim 2  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         5 . The method of  claim 4  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         6 . The method of  claim 1  wherein the inflammatory disease is vasculitis.  
     
     
         7 . The method of  claim 1  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         8 . The method of  claim 7  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         9 . The method of  claim 1  wherein the disease is a nasolacrimal duct or eustachean tube disease.  
     
     
         10 . The method of  claim 1  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         11 . The method of  claim 1  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         12 . The method of  claim 1  wherein the antihistamine or decongestant is selected from the group consisting of astemizole(histamine H1-receptor antagonist), azatidine, brompheniramine, clemastine, chlorpheniramine, cromolyn, cyproheptadine, diphenylimidazole, diphenhydramine hydrochloride, hydroxyzine, glycyrrhetic acid, homochlorocyclizine hydrochloride, ketotifen, loratadine, naphazoline, phenindamine, pheniramine, promethazine, terfenadine, trimeprazine, tripelennamine, and tranilast.  
     
     
         13 . The method of  claim 1  wherein the decongestant is phenylpropanolamine or pseudoephedrine.  
     
     
         14 . The method of  claim 1  wherein the composition is biodegradable.  
     
     
         15 . The method of  claim 1  wherein the composition is non-biodegradable.  
     
     
         16 . The method of  claim 1  wherein the composition further comprises a polymer.  
     
     
         17 . The method of  claim 16  wherein the polymer is biodegradable.  
     
     
         18 . The method of  claim 16  wherein the polymer is non-biodegradable.  
     
     
         19 . The method of  claim 1  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         20 . The method of  claim 1  wherein the composition further comprises a poly(caprolactone).  
     
     
         21 . The method of  claim 1  wherein the composition further comprises a poly(lactic acid).  
     
     
         22 . The method of  claim 1  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         23 . The method of  claim 1  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         24 . The method of  claim 1  wherein the composition further comprises a polyester.  
     
     
         25 . The method of  claim 1  wherein the composition further comprises a polyurethane.  
     
     
         26 . The method of  claim 1  wherein the composition further comprises a polyanhydride.  
     
     
         27 . The method of  claim 1  wherein the composition further comprises a gelatin.  
     
     
         28 . The method of  claim 1  wherein the composition is in the form of a paste.  
     
     
         29 . The method of  claim 1  wherein the composition is in the form of a film.  
     
     
         30 . The method of  claim 1  wherein the composition is in the form of a spray.  
     
     
         31 . The method of  claim 1  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.  
     
     
         32 . The method of  claim 1  wherein the antihistamine or decongestant or the composition comprising the antihistamine or decongestant is administered percutaneously to the exterior surface of the body passageway.  
     
     
         33 . The method of  claim 1  wherein the antihistamine or decongestant or the composition comprising the antihistamine or decongestant is applied to the adventitial surface of the body passageway.  
     
     
         34 . A method for treating or preventing an inflammatory disease associated with narrowing or obstruction of a body passageway, comprising delivering to smooth muscle cells via the adventitia of the body passageway of a patient in need thereof a therapeutically effective amount of an antihistamine or decongestant or a composition comprising an antihistamine or decongestant, such that the inflammatory disease is treated.  
     
     
         35 . The method of  claim 34  wherein the inflammatory disease is a gastrointestinal tract disease.  
     
     
         36 . The method of  claim 35  wherein the gastrointestinal tract disease is selected from the group consisting of pancreatitis, Crohn's Disease, Ulcerative Colitis, Ulcerative Proctitis, and Primary Sclerosing Cholangitis.  
     
     
         37 . The method of  claim 35  wherein the gastrointestinal tract disease is a benign stricture.  
     
     
         38 . The method of  claim 37  wherein the benign stricture is selected from the group consisting of bile duct, esophagus, duodenum, small bowel and colon strictures.  
     
     
         39 . The method of  claim 34  wherein the inflammatory disease is vasculitis.  
     
     
         40 . The method of  claim 34  wherein the inflammatory disease is a respiratory tract disease.  
     
     
         41 . The method of  claim 40  wherein the respiratory tract disease is asthma, hypersensitivity pneumonitis, asbestosis, silicosis, chronic bronchitis, or chronic obstructive airway disease.  
     
     
         42 . The method of  claim 34  wherein the disease is a nasolacrimal duct or eustachean tube disease.  
     
     
         43 . The method of  claim 34  wherein the body passageway is selected from the group consisting of lacrimal ducts, trachea, bronchi, bronchiole, nasal airways, sinus passages, eustachian tubes, and external auditory canal.  
     
     
         44 . The method of  claim 34  wherein the body passageway is selected from the group consisting of an esophagus, a stomach, a duodenum, a small intestine, a large intestine, biliary tracts, a ureter, a bladder, and a urethra.  
     
     
         45 . The method of  claim 34  wherein the antihistamine or decongestant is selected from the group consisting of astemizole(histamine HI-receptor antagonist), azatidine, brompheniramine, clemastine, chlorpheniramine, cromolyn, cyproheptadine, diphenylimidazole, diphenhydramine hydrochloride, hydroxyzine, glycyrrhetic acid, homochlorocyclizine hydrochloride, ketotifen, loratadine, naphazoline, phenindamine, pheniramine, promethazine, terfenadine, trimeprazine, tripelennamine, and tranilast.  
     
     
         46 . The method of  claim 34  wherein the decongestant is phenylpropanolamine or pseudoephedrine.  
     
     
         47 . The method of  claim 34  wherein the composition is biodegradable.  
     
     
         48 . The method of  claim 34  wherein the composition is non-biodegradable.  
     
     
         49 . The method of  claim 34  wherein the composition further comprises a polymer.  
     
     
         50 . The method of  claim 49  wherein the polymer is biodegradable.  
     
     
         51 . The method of  claim 49  wherein the polymer is non-biodegradable.  
     
     
         52 . The method of  claim 34  wherein the composition further comprises a copolymer of lactic acid and glycolic acid.  
     
     
         53 . The method of  claim 34  wherein the composition further comprises a poly(caprolactone).  
     
     
         54 . The method of  claim 34  wherein the composition further comprises a poly(lactic acid).  
     
     
         55 . The method of  claim 34  wherein the composition further comprises a copolymer of poly(lactic acid) and poly(caprolactone).  
     
     
         56 . The method of  claim 34  wherein the composition further comprises a poly(ethylene-vinyl acetate).  
     
     
         57 . The method of  claim 34  wherein the composition further comprises a polyester.  
     
     
         58 . The method of  claim 34  wherein the composition further comprises a polyurethane.  
     
     
         59 . The method of  claim 34  wherein the composition further comprises a polyanhydride.  
     
     
         60 . The method of  claim 34  wherein the composition further comprises a gelatin.  
     
     
         61 . The method of  claim 34  wherein the composition is in the form of a paste.  
     
     
         62 . The method of  claim 34  wherein the composition is in the form of a film.  
     
     
         63 . The method of  claim 34  wherein the composition is in the form of a spray.  
     
     
         64 . The method of  claim 34  wherein the composition comprises microspheres having an average size ranging from about 0.5 μm to 200 μm.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.